Literature DB >> 7629392

Treatment of distant metastases of differentiated thyroid carcinoma.

M Schlumberger1, C Challeton, F De Vathaire, C Parmentier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7629392     DOI： 10.1007/bf03349735

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  9 in total

Review 1.  Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer.

Authors:  H R Maxon; H S Smith
Journal:  Endocrinol Metab Clin North Am       Date:  1990-09       Impact factor: 4.741

2.  Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma.

Authors:  M Schlumberger; M Tubiana; F De Vathaire; C Hill; P Gardet; J P Travagli; P Fragu; J Lumbroso; B Caillou; C Parmentier
Journal:  J Clin Endocrinol Metab       Date:  1986-10       Impact factor: 5.958

3.  Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels.

Authors:  F Pacini; F Lippi; N Formica; R Elisei; S Anelli; C Ceccarelli; A Pinchera
Journal:  J Nucl Med       Date:  1987-12       Impact factor: 10.057

4.  Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays.

Authors:  M Schlumberger; O Arcangioli; J D Piekarski; M Tubiana; C Parmentier
Journal:  J Nucl Med       Date:  1988-11       Impact factor: 10.057

5.  A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

Authors:  K Shimaoka; D A Schoenfeld; W D DeWys; R H Creech; R DeConti
Journal:  Cancer       Date:  1985-11-01       Impact factor: 6.860

6.  Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables.

Authors:  J J Ruegemer; I D Hay; E J Bergstralh; J J Ryan; K P Offord; C A Gorman
Journal:  J Clin Endocrinol Metab       Date:  1988-09       Impact factor: 5.958

7.  Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial.

Authors:  S D Williams; R Birch; L H Einhorn
Journal:  Cancer Treat Rep       Date:  1986-03

8.  External radiotherapy in thyroid cancers.

Authors:  M Tubiana; E Haddad; M Schlumberger; C Hill; P Rougier; D Sarrazin
Journal:  Cancer       Date:  1985-05-01       Impact factor: 6.860

9.  Distant metastases in differentiated thyroid cancer: long-term results of radioiodine treatment and statistical analysis of prognostic factors in 214 patients.

Authors:  D Casara; D Rubello; G Saladini; V Gallo; G Masarotto; B Busnardo
Journal:  Tumori       Date:  1991-10-31
  9 in total
  1 in total

1.  Bioluminescent monitoring of NIS-mediated (131)I ablative effects in MCF-7 xenografts.

Authors:  Malavika Ghosh; Sanjiv Sam Gambhir; Abhijit De; Kent Nowels; Michael Goris; Irene Wapnir
Journal:  Mol Imaging       Date:  2006 Apr-Jun       Impact factor: 4.488
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.